Signaling pathways initiated at the membrane establish and maintain cell fate during development and can be harnessed in the nucleus to generate induced pluripotent stem cells (iPSCs) from differentiated cells. Yet, the impact of extracellular signaling on reprogramming to pluripotency has not been systematically addressed. Here, we screen a lentiviral library encoding ~100 million secreted and membrane-bound antibodies and identify multiple antibodies that can replace Sox2/c-Myc or Oct4 during reprogramming.
Introduction
During development, cellular diversity arises through a series of choreographed cell fate changes that are temporally ordered, largely irreversible and conserved among species.
These changes are guided by signals that transit the cell membrane and converge in the nucleus where they rewire transcriptional programs to produce coordinated patterns of gene expression that specify a new cellular identity. Surprisingly, in 2006, Yamanaka and Takahashi found that the transient expression of only a few transcription factors was sufficient to reverse cellular differentiation and produce induced pluripotent stem cells (iPSCs) that recapture the developmental potency of embryonic cells. [1] [2] [3] [4] Since this discovery, direct reprogramming using transcription factors has emerged as a robust general method to induce cell fate changes that do not normally occur during development such as the direct conversion of fibroblasts into neurons or cardiomyocytes [5] [6] [7] [8] . This increased understanding of how to program cell fate from within the nucleus has led to a marked shift in approaches to model or treat disease using human cell types produced in vitro, and also informed thinking about how nuclear events may contribute to de-differentiation in other contexts. 9 In contrast, the potential for membrane-to-nucleus signaling pathways to replace transcription factors during reprogramming has not been systematically addressed.
One barrier to understanding mechanisms underlying induced pluripotency is that reprogramming inefficient and involves stochastic steps, making it difficult to identify pathways involved in successful reprogramming using bulk biochemical analyses or proteomics. [10] [11] [12] Although small molecule and shRNA/CRISPR based screens have uncovered several signaling pathways involved in reprogramming, these screens are limited by their reduced capacity to perturb key signaling modalities such as proteinprotein interactions. [13] [14] [15] [16] [17] Furthermore, small molecule based reprogramming has not been widely adopted, perhaps due to the potential for unknown off target effects. 18, 19 Thus, it is likely that some, or perhaps even the majority of biochemical events that can trigger reprogramming to pluripotency, remain unknown.
One powerful means to establish the function of cell signaling cascades is to employ antibodies to perturb protein function or protein-protein interactions. Historically, synthetic combinatorial antibody libraries have been useful to identify antibodies directed at known targets. [20] [21] [22] [23] [24] [25] [26] [27] [28] Here, however, we wished to identify unknown pathways.
To accomplish this we took advantage of the lentiviral gene delivery system. By encoding a synthetic combinatorial antibody library in lentivuses, we can transduce fibroblasts with the library such that each cell will express one or several unique antibody proteins, effectively converting each cell into an autonomous biochemical reaction compartment. Clonal colonies that emerge will contain the gene sequence of a candidate autocrine reprogramming antibody. This sequence can be recovered and used to produce the antibody in soluble, secreted or membrane-bound versions for confirmation of activity and further mechanistic investigations. Therefore, for this study we adapted a previously described combinatorial antibody library for use in unbiased cell based screening with clonal selection of proliferating iPSC colonies. To accomplish this, we generated a lentiviral library in which each lentivirus encodes a unique antibody sequence that is either targeted for secretion or membrane-tethered, with the total library complexity comprising ~100 million unique specificities. 27, [29] [30] [31] This autocrine antibody platform enables us to survey a very large number of potential independent specificities, which are equal to the number of original cells plated multiplied by the MOI, in this case > 10 8 specificities in one experiment, without prior knowledge of a target.
This platform allows the screening of a large number of molecules compared with previous studies that involved pre-selection of antibodies against a desired target. 32 Using the autocrine antibody reprogramming platform, we isolated multiple antibodies that replaced either Sox2/c-Myc or Oct4 in generating iPSCs. Identifying the target of one Sox2 replacement antibody showed that it binds to Basp1, a protein not previously implicated in pluripotency or identified in shRNA screens. 16, 17 Our mechanistic studies show that Basp1 inhibition leads to increased nuclear Wt1 activity and increased expression of Esrrb and Lin28, prior to Sox2 induction, which differs from previously reported reprogramming pathways, validating the autocrine antibody reprogramming platform as a discovery tool to identify new biologics and pathways that induce pluripotency or impact cell fate plasticity.
Results

The autocrine antibody library reprogramming platform.
To allow us to select for and recover antibody sequences that promoted clonal growth of pluripotent stem cells from individual transduced fibroblasts without prior selection on a known target, we took advantage of the ability of lentiviruses to insert in the genome of cells. To facilitate lentiviral delivery and sequence recovery, the antibodies were encoded in a single chain form in which the entire recognition domain of the CDR3 region is encoded by a ScFv domain fused to the Fc region from human IgG1, as described previously. 31 If cells transform into iPSCs they will grow up as clones of single cells that will contain one or more lentiviral insertions (Figure 1a ). Because the antibody coding sequences are integrated in the genome, their sequences can be recovered by PCR and re-tested for efficacy ( Figure 1a) . Candidate antibodies can also be targeted for secretion or to various cellular compartments, which can increase their effective concentration. For this study, we a library comprising both secreted and membranetethered antibodies ( Figure S1a ).
Identifying antibodies that replace Sox2/cMyc in reprogramming
We wished to determine whether the autocrine antibody platform could identify antibodies that induce reprogramming without use of the transcription factors Sox2 and c-Myc. To achieve this, we transduced 10 8 mouse embryonic fibroblasts (MEFs) with doxycycline-inducible lentiviruses encoding Klf4 and Oct3/4, (KO) but not Sox2 or cMyc (SM) and the autocrine antibody lentiviral library (MOI = 0.8) (Figure 1a ). This resulted in a population of ~1 x 10 8 MEFs, each theoretically expressing one or more unique antibody sequences. In the primary screen, we also included an shRNA targeted against p53 to increase reprogramming efficiency. This shRNA was not present in the subsequent confirmation experiments. Fourteen days after induction, MEFs infected with the antibody library and the KO transcription factors produced approximately 10 iPSC-like colonies per one million MEFs plated ( Figure S1b) . We compared these cells to positive control cells expressing all four factors (Oct3/4, Sox2 Klf4, and cMyc, OSKM) and negative control MEFs transduced with membrane-targeted tdTomato plus KO and p53 shRNA. Positive controls produced ~500 colonies per 1 million cells plated, while no colonies arose in the negative control wells ( Figure S1b ). Because only one copy of each antibody is present, the probability of an antibody with reprogramming activity resulting in detectable pluripotency may be limited by the low efficiency of reprogramming (0.1 -2%). Therefore, we initially screened using a low stringency metric (colony formation) to capture 103 iPSC-like colonies and expanded them in independent wells (Figure 1b ). After single cell dissociation, twenty-five of the primary colonies gave rise to secondary colonies that could be propagated as cell lines under standard ES/iPS cell culture conditions. Next, to identify bona fide potential iPSC colonies tested them for increasingly stringent pluripotency markers, alkaline phosphatase, SSEA1 and Nanog and identified eight triple positive colonies ( Figure   1c ). Notably, more colonies expressed the early (AP) and intermediate (SSEA1) markers than Nanog, while all Nanog positive colonies were triple positive, suggesting that antibody induced reprogramming was following previously reported steps.
Two-step autocrine antibody selection identifies antibodies that replace Oct4
We next examined whether the autocrine antibody platform could identify antibodies that replace Oct4 in reprogramming, which has proven challenging in other studies. 33, 34 Therefore, to increase our chance of success, we performed a two-step screen with a design parallel to the Sox2/c-Myc screen, except that cells were transduced with Klf4, Sox2, and cMyc (KSM) but not Oct4 (Figure 1a ). Since the Sox2 screen suggested that SSEA-1 is a representative early indicator of reprogramming we selected the ~50 SSEA positive colonies we found in a screen of ~10 8 MEFs (no positives were present in KSM only wells) ( Figure. 1d and e). We next used PCR to amplify these antibody sequences and subcloned them into new lentiviruses to generate a secondary Oct4focused library (Figure 1a ). We next repeated the original screen using the focused library, which generated more than 50 SSEA1-positive colonies/10 6 cells, representing a ~100-fold increase in activity over the naïve library ( Figure 1e ). We picked individual colonies from the focused screen and clonally expanded them into lines. Cell lines established from the focused library expressed the pluripotency markers Nanog and Oct4 (Figure 1f ). These experiments validate two different strategies for employing the AutoAb platform to identify antibodies that replace reprogramming factors.
Validation of iPSCs generated using antibodies to replace Sox2 or Oct4.
To functionally validate the antibody hits, we used genomic PCR to recover ScFv antibody coding sequences from two independent Nanog-positive secondary lines from each screen. DNA sequencing showed that each line harbored a unique CDR3 region ( Figure S2a and b, Table S1 ). To confirm their function, we subcloned these sequences into two different viral backbones, containing either signal sequences for secretion or for membrane tethering (MTA). These lentiviruses were then tested in new reprogramming assays. When targeted to the membrane, both Sox2 replacing antibodies (SoxAb1 and SoxAb2) and Oct4 replacing antibodies (OctAb1 and OctAb2)
produced Nanog-positive colonies in the absence of Sox2 or Oct4 (Figure 2a and b) .
Similar results were observed with lentivirally-encoded secreted forms of the antibodies (data not shown).
While lentiviral encoded antibodies are facile tools to identify targets and pathways relevant for reprogramming, we also wished to test whether exogenous application of soluble versions of the antibodies identified in this screen could induce reprogramming.
To test this we produced a soluble form of SoxAb2 antibody and showed that adding this protein directly to the culture media (at ~1.0 ug/ml) can also induce reprogramming in the absence of Sox2 (Figure 2a ). This serves as a proof of concept that antibodies identified using lentivirally encoded secreted molecules and also have activity when produced exogenously. However, as these initial antibody hits are likely to serve as a starting point for optimizing exogenously applied antibodies that would need to be optimized for protein production, biding affinity, etc. we did not further address this mechanistically. Finally, we also tested the lentiviral Sox2 or Oct4 replacing antibodies with transcription factor cocktails lacking Oct4 or Sox2 respectively, and observed no colonies (data not shown), indicating that the antibodies we identified exhibit pathway based selectivity.
To demonstrate conclusively that antibodies can replace Sox2/c-Myc or Oct4 in reprogramming to pluripotency we performed a series of functional tests of the iPSC lines ( Table 1 and Table S1 ). iPSCs generated with the subcloned and sequenced We next tested whether these lines could contribute to three germ layers in chimeric mouse embryos. iPSCs derived from albino CD1 fibroblasts using either SoxAb1 or SoxAb2 were injected into C57/BL6 blastocysts (pigmented background). Pups showed significant contribution across all three embryonic germ layers and survived to adulthood (Figure 2f , S2i, S2j, and Table 1 ). These results demonstrate that iPSCs produced with antibodies can pass the standard functional tests used to designate iPSCs as pluripotent stem cells.
To more comprehensively characterize the iPSCs we performed RNA-Seq on triplicate Figure S2m ). Inspection of these gene lists did not uncover dysregulation of any known pluripotency genes (Table S2) . Quantitative RT-PCR experiments also confirmed that pluripotency genes (Oct4, Sox2, Nanog, Lin28, Sall4, Esrrb, Dppa2, and Zscan4b) were upregulated in SoxAb1 and 2 iPSC lines relative to fibroblasts expressing KOM alone ( Figure S2k) . These results show that multiple antibodies selected from combinatorial libraries can replace transcription factors in producing iPSC lines that exhibiting the functional and molecular hallmarks of high-quality pluripotent stem cell lines.
SoxAb2 binds to and antagonizes Basp1
Next, we wished to determine whether we could use these antibodies to identify new pathways that promote reprogramming to pluripotency. The SoxAb2 iPSCs were the most similar to the TEC competent PSCs and we were able to purify sufficient amounts of this antibody to show that it can act as a biologic when supplied in the reprogramming dish (Figure 2a ), making it an attractive candidate to follow up mechanistically.
However, Sox2 has previously been replaced by inhibiting Tgf-b signaling, inhibiting
Src-kinase or antagonizing the induction of mesoderm genes. 13, 15, 35, 36 To determine whether the SoxAb2 involved these known mechanisms, we performed a series of experiments that showed that SoxAb2 did not impact Tgf-b signaling (Smad2 vimentin, which is a common contaminant in mass spectrometry, the most abundant protein was brain acid soluble protein 1 (Basp1) ( Figure S3d ).
Basp1 is a 22 kDa calmodulin-binding protein that is localized to lipid insoluble membrane domains and cellular outgrowths such as pseudopodia and filopodia [37] [38] [39] Figure 3c ). In addition, we showed that SoxAb2 immunoprecipitates both native and overexpressed Basp1, indicating that Basp1 is present in MEFs at the membrane and is a direct target of SoxAb2 (Figure 3d and S3e).
Antibodies frequently act as antagonists by blocking protein-protein interactions.
However, some antibodies can have agonist or catalytic activities. To test whether (also known as E-cadherin) ( Figure S3f-h) . 40, 41 Inhibiting Basp1 expression promotes reprogramming These Oct4::GFP-positive colonies were expanded into lines that propagated for at least ten passages under standard mESC culture conditions while retaining properties of pluripotency ( Figure S3i and Table S1 ). PCR with primers specific for Klf4, Oct4,
and Sox2 transgenes confirmed that Basp1 knockdown lines did not harbor transgenic Sox2 (Figure S3j ). Similar to SoxAb2 iPSC lines, Basp1 knockdown lines expressed the pluripotency markers SSEA1, Oct4, Nanog, and endogenous Sox2 (Figure 3f) . The 
Basp1 inhibits reprogramming through repression of Wt1
Knocking down Basp1 and expressing an antibody that binds to Basp1 result in similar cell reprogramming outcomes, suggesting that Basp1 may repress an activator of reprogramming. In some cell types, Basp1 has been shown to translocate from the membrane to the nucleus where it acts as a transcriptional repressor of Wilm's tumor suppressor 1 (Wt1). 42, 43 Therefore, we hypothesized that SoxAb2 binding to Basp1 or (reduction of Basp1 via shRNA) de-repress Wt1, leading to Wt1-mediated transcriptional activation and reprogramming.
To test this hypothesis we asked whether Basp1 interacts with Wt1.
Immunoprecipitation experiments revealed that Basp1 interacts with Wt1 in MEFs ( Figure S4a) . Since Wt1 and Basp1 interact in cells undergoing reprogramming, we next tested whether Wt1 expression can also replace Sox2 in reprogramming to pluripotency. Indeed, overexpression of Wt1 (the KTS-minus isoform known to act as a transcription factor) induced Oct4::GFP + colonies in the absence of Sox2 (Figure 4a ).
Next, we established iPSC lines generated with Wt1 instead of Sox2 (Table 1 and S1).
These Wt1 iPSC lines displayed typical mESC morphology and expressed endogenous pluripotency genes (Figure 4b, S4b , and S4c). The global transcriptional profiles of WT1 iPSCs were highly similar to TEC competent iPSCs and ESCs and distant from
MEFs (Figure 4c, S4d, and S4e) . Functional tests showed that Wt1 iPSCs can generate cells from all three embryonic germ layers in vitro and can also contribute to chimeric mice with germline transmission (Figure 4d and S4f) . These results demonstrate that Wt1 can replace Sox2 in generating functional iPSCs, supporting the idea that Basp1 inhibition acts through de-repression of WT1, either by directly blocking protein protein interactions, inhibiting Basp1 translocation or an alternative mechanism.
To further test this idea, we asked whether Basp1 and Wt1 exhibit synergistic or antagonistic activities during reprogramming. When Wt1 and Basp1 shRNAs were coexpressed, the number of Oct4::GFP + colonies did not significantly increase, suggesting that Basp1 and Wt1 act in the same pathway (Figure 4a) . Conversely, when Basp1 was overexpressed with Wt1, the number of Oct4::GFP + colonies was significantly reduced by 68% ± 0.063% (p < 0.0003) demonstrating that Basp1 can interfere with Wt1 reprogramming activity (Figure 4a) . These results are consistent with a model in which Basp1 in fibroblasts represses Wt1 activity and when this repression is relieved by SoxAb2 or by knocking down Basp1, Wt1 activates transcriptional networks that promote reprogramming.
Wt1 induces expression of Lin28 and Esrrb during reprogramming
To examine the mechanism by which the Basp1-Wt1 signaling pathway promotes reprogramming we wished to examine early molecular events during the reprogramming process. These can be difficult to detect because of the low efficiency at which cells are reprogrammed. 11, 44 However, rare events during reprogramming can be detected by However, Wt1/Basp1 treatment did not alter expression of cell cycle regulators or detectably upregulate endogenous Sox2 during early or late stages of reprogramming ( Figure S4g) . Alternatively, Basp1/Wt1 signaling could replace Sox2 by inducing genes downstream of Sox2 that ultimately lead to Sox2 induction such as Nanog. 13 However, we did not observe significant upregulation of Nanog at day 4 or 12 of reprogramming, further suggesting that the Basp1/Wt1 pathway identified by SoxAb2 operates through a novel mechanism (Figure 4e) .
In contrast, Lin28 and Esrrb were significantly upregulated in KOM cells after twelve days of treatment with either SoxAb2 or Wt1/Basp1-shRNA (Figure 4e ). Cdh1 was also upregulated in cells treated with SoxAb2, or Wt1/Basp1-shRNA, but did not reach significance when corrected for multiple comparisons (Figure 4e) . Both Lin28 and Esrrb have been previously shown to be downstream of Sox2 during reprogramming. [45] [46] [47] Furthermore, Esrrb has been reported to positively regulate Sox2 expression, suggesting a possible mechanism by which endogenous Sox2 is ultimately activated during Basp1/Wt1 reprogramming. 47 These data support a model in which antibody-mediated antagonism of Basp1 converts Figure 4h and S4h). This demonstrates that Lin28 and Esrrb can also promote reprogramming in the absence of Sox2, supporting our model.
Inhibiting Basp1 or increasing Wt1 signaling can promote reprogramming in the absence of ectopic Sox2. This raises the question of whether Basp1 overexpression or WT1 reduction would inhibit reprogramming. To address this, we derived MEFs from an optimized reprogrammable mouse strain in which KOSM can be uniformly induced using doxycycline. 10 Overexpression of Basp1 and knockdown of Wt1 significantly reduced the number of Nanog-positive colonies by 71.6% ± 0.06% and 75% ± 0.04% (p < 0.0081) respectively (Figure 4i) . Similarly, knockdown of Wt1 reduced Esrrb, Lin28
and its downstream target cMyc in mESCs (v6.5) and iPSCs ( Figure S4i) . These experiments show that these pathways intersect and suggest that high expression of
Basp1 and/or low Wt1 activity can impede reprogramming by the KOSM factors.
Here we identified a new candidate pathway involving Basp1 inhibition/reduction, Wt1 activation, and Esrrb/Lin28 activation that is involved in reprogramming to pluripotency. Figure S5) . In contrast, a gene that is not regulated by WT1 (RPL30) and a genomic region void of genes we did not observe enrichment of WT1 over control.
These results show that WT1 occupies genomic regions distal to LIN28A and B TSS and, therefore, could directly regulate their transcription.
Together, these experiments show that the autocrine antibody platform can identify new pathways relevant to cell fate plasticity that operate in artificial environments such as induced pluripotency as well as in endogenous reprogramming situations such as cancer progression.
Discussion
This study validates the autocrine antibody platform for use in the discovery of biologics and pathways that induce pluripotency, building on powerful studies of other groups that have used pre-selected antibody libraries to alter ES cell fate. 32 Together these studies highlight the power of this approach in diverse cell based screening contexts. For example, by performing these screens we identify at least three new methods to produce iPSCs. In addition, we establish that perturbing membrane-to-nucleus signaling pathways is a useful method to identify new mechanisms that induce pluipotency, which would perhaps not have been predicted due to the success and wide adoption of transcription factor-based reprogramming methods acting directly in the nucleus.
Here, we identify antibodies that can replace Sox2/c-Myc and Oct4 during reprogramming, but we have not yet been able to replace Klf4. Replacing three of the four reprogramming factors with antibodies suggests that it may one day be possible to induce pluripotency solely through the use of antibodies. Fully antibody-based induction of pluripotency could offer several practical advantages. First, applying soluble antibodies to cells in solution offers a means to ensure that each cell receives the same biochemical trigger as every other cell, which is difficult to accomplish with methods that rely on cell transduction or transformation. Second, using soluble antibodies to reprogram cells could provide a facile method to generate iPSCs that have not experienced any direct nuclear perturbation, thus limiting threats to the iPSC genome.
As such, RNA transfection has emerged as a popular non-integrating reprogramming approach. However, RNA-based reprogramming requires frequent transfection of the cells and individual iPSCs are likely to have experienced different ratios and levels of reprogramming factors which could lead to increased variability among iPSC lines. 48 Other groups have used cocktails of small molecules to induce pluripotency in mouse cells. 33 While an appealing approach, small molecules can exhibit unknown off-target effects at the concentrations required. In contrast, antibodies typically bind their antigens with high specificity and have been shown to exhibit >200-fold improvements in selectivity when compared to small molecules aimed at the same target. 49 Finally, once a target is identified, antibodies can be readily "evolved" to produce molecules with increased binding affinity or stability. Together these unique features of antibodies and our demonstration that multiple soluble and membrane-tethered antibodies can induce reprogramming, establishes this as a promising new avenue for research. Although we
have not yet identified an antibody to replace Klf4 in reprogramming, we believe that these studies support the initiation of larger scale screens and additional analyses of reprogramming pathways may ultimately identify a non-integrating all-antibody method for reprogramming. Alternatively, if reprogramming entirely with antibodies is not possible, reprogramming with a mixture of antibodies and other chemical or RNA-based inducers may still result in iPSC production methods with improved safety or reproducibility.
Another advantage of reprogramming with genetically encoded antibodies is that this approach is compatible with several well-validated methods to improve antibody efficacy and thus increase reprogramming efficiency. One method, akin to phenotypic screening, is to mutagenize the identified antibodies through PCR or similar approaches, then perform new selections for iPSCs. This approach can identify antibodies with the most effective balance of kinetic and structural features and thus rapidly optimize reprogramming efficiencies, even without knowledge of the antibody ligand. In cases where the ligand of the antibody is abundant enough for target identification, the power of combinatorial antibody library screening can be further exploited. By screening for antibodies that bind to a known ligand, either via traditional phage display, or through cell-based screening, one can identify new antibodies directed to the same ligand that may have very different binding sites or mechanisms. Importantly, using several nonoverlapping antibodies in the same cocktail might lead to further improvements in reprogramming efficiency. It is also possible that the inherent stochastic nature of reprogramming may be due to our lack of knowledge of more efficient pathways than those engaged by OSKM mediated reprogramming. In this case, wider adoption and continued application of the unbiased Autocrine antibody library platform may uncover new reprogramming mechanisms that are inherently more efficient than current protocols.
Experimental Procedures
Cell culture and iPS cell generation µm PVDF filters. Lentiviral infections were performed as previously described. 50 Expression was induced with 5 µg/ml doxycycline. The first day of doxycycline addition was denoted as day 0 of expression. For the first seven days cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS). After 7 days cells were cultured in mES cell media supplemented 15% Knock-out serum replacement, LIF. All colony counts were performed on day 14 unless noted otherwise.
Gene knockdown and overexpression validation.
ShRNAs were purchased from Sigma Mission collection (Basp1: TRCN0000190229 and TRCN0000202255; WT1: TRCN0000054465 and TRCN0000054464). The Wt1-Kts overexpression plasmid was generated by the Jaenisch laboratory (Addgene, Plasmid#41082).
The following antibodies were used at a concentration of 1:500 mouse-anti-Oct4
(SantaCruz), rabbit-anti-Nanog (Cosmobio), mouse anti-Sox2 (R&D) and GFP-coupled anti-SSEA-1(ESI-BIO) rabbit anti-Basp1 (Abcam). For in vitro differentiation, iPS cells were added onto low attachment plates at 1x10 5 51 Reads were then aligned using STAR 52 and counts were generated using HTSeq. 53 RNA-Seq data was analyzed using R an open source programming language and environment for statistical computing and visualization.
Differential gene expression analysis was conducted using DESeq2 and gene expression was normalized using vsd transformation to generate heatmaps. 54 Immunoprecipitation and Western Blotting. 
